HDHemaniswarri Dewi Dewadas

Hemaniswarri Dewi Dewadas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hemaniswarri Dewi Dewadas has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Yang Mooi Lim

    Centre for Cancer Research, M. Kandiah Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Kajang 43000, Selangor, Malaysia

    7 shared publications
  • Chai Nien Foo

    Centre for Cancer Research, M. Kandiah Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Kajang 43000, Selangor, Malaysia

    4 shared publications
  • Ailyn Irvita Ravinther

    Centre for Cancer Research, M. Kandiah Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Kajang 43000, Selangor, Malaysia

    2 shared publications
  • Bachok Norsa'ADah

    Biostatistics and Research Methodology Unit, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia

    1 shared publication
  • Boon Keat Chin

    Doc Holding Sdn. Bhd. Puchong Selangor Malaysia

    1 shared publication
  • Chai Nien Foo

    Centre for Cancer Research, M. Kandiah Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Kajang 43000, Selangor, Malaysia

    1 shared publication

Latest Publications

  • Open Access

    Anticancer Activities and Molecular Mechanisms of 2-Methoxy-1,4-Naphthoquinone: A Systematic Review of Preclinical Evidence

    by Yu Shan Tan, Jia Ying Chi, Soon Yan Tan, Hemaniswarri Dewi Dewadas, Yang Mooi Lim

    Background/Objectives: 2-Methoxy-1,4-naphthoquinone (MNQ) is a naturally occurring, redox-active compound with reported anticancer activity, but its preclinical evidence has not been systematically reviewed. This review evaluated the anticancer-related activities and associated molecular mechanisms of MNQ across preclinical cancer models. Methods: PubMed, Scopus, Cochrane Library, Embase, and Web of Science were systematically searched, with the final search performed on 26 October 2026. Original English-language studies evaluating the anticancer effects or cancer-related biological activities of MNQ were included. Findings were narratively synthesised and mapped to the Hallmarks of Cancer framework. Risk of bias was assessed using adapted OHAT and SYRCLE tools for in vitro and in vivo evidence, respectively. Results: Fourteen studies were included, all involving in vitro experiments, with one also reporting an in vivo hepatoma xenograft study. MNQ showed cytotoxic and antiproliferative activities, alongside apoptosis, necrosis, cell-cycle alterations, oxidative stress, DNA damage, mitochondrial dysfunction, and suppression of glycolysis, migration, and invasion. Alterations in autophagy-related markers, inflammatory and cellular stress responses, inhibition of EBV early antigen activation, and alterations in MAPK, PI3K/Akt, NF-κB, and PKC-related signalling were also reported. The in vivo study reported reduced tumour growth. Risk-of-bias assessments identified methodological reporting limitations in in vitro studies and predominantly unclear risk-of-bias judgements for the in vivo study. Conclusions: Current preclinical evidence suggests that MNQ affects biological processes associated with six Hallmarks of Cancer, highlighting its potential for further anticancer investigation. Nevertheless, the evidence remains predominantly in vitro, while experimental heterogeneity and methodological limitations emphasise the need for further mechanistic and in vivo validation.

  • Rab proteins as diagnostic biomarkers for Parkinson’s disease: a systematic review

    by Ailyn Ravinther, Hemaniswarri Dewi Dewadas, Ruijia Hou, Nicole Tze Er Lee, Cheng-Ting Chien, Chai Nien Foo, Yang Mooi Lim

    Purpose: Parkinson’s disease (PD) is a neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons. PD is typically diagnosed at late-stage, concurrent with loss of up to 70% of these neurons so patient care could be improved by diagnosis at prodromal stages. The occurrence of Parkinsonian-like diseases also understores the importance of accurate differential diagnosis, yet no biomarkers are currently used in clinical settings to minimize diagnostic errors. The Rab family of GTPases has been implicated in the PD pathogenesis, with protein levels elevated in pre-clinical models. This review evaluates the utility of Rab proteins as a biomarker for PD. Methods: A systematic search was performed following PRISMA guidelines using PubMed, Scopus, Cochrane, SAGE, OVID and Web of Science (references up to November 2025). Search keywords included: "Parkinson", "Rab" and "biomarker". Results: Out of 1404 records identified, 27 articles were sought for retrieval after duplicate removal and title/abstract screening. The search yielded 13 articles that fit the inclusion criteria. 8 different Rab proteins of interest and/or their phosphorylated forms were reported as differentially expressed in PD patients in these papers. Of the 8 Rab proteins, Rab35 had a consistent elevation. However, this was observable from a single research group, presenting the need for independent validation of Rab35 as a diagnostic biomarker for idiopathic PD (iPD). In contrast, though preliminary, pRab10 may have relevance for patient stratification and monitoring drug response in PD patients. However, with the small evidence base, further research with larger sample sizes, patient sub-types and other contributing factors will be vital before integration into clinical practice. Conclusion: Overall, the evidence for Rab proteins as diagnostic biomarkers is emerging rather than established. Inconsistent reporting, small and frequently overlapping samples prevented quantitative synthesis.

  • Open Access

    Animal Studies on the Effects of Edible Bird’s Nest on Cognitive Function and Neuroprotection: A Systematic Review

    by Jiaying Chi, Yu Shan Tan, Hemaniswarri Dewi Dewadas, Chai Nien Foo, Yang Mooi Lim

    Objectives: This systematic review aims to evaluate the effects of Edible Bird’s Nest (EBN) extract on cognitive function and neuroprotection in animal models and systematically review the relevant research evidence. Methods: A systematic search was conducted in the databases of PubMed, Scopus, Web of Science, EMBASE, Taylor Francis, Wiley, and Cochrane Library for relevant research published up to October 2025. Search terms included “Edible Bird’s Nest”, “Bird’s Nest Extract”, “EBN”, “Swiftlet nest”, “Collocalia”, “Cognitive”, “Memory”, “Learning”, “Neuroprotection”, “Brain”, “Neural”, “Neurotrophic”, “Animal”, “Mice”, “Mouse”, “Rat”, “Rats”, “In vivo”, and “Model”. Two researchers independently screened all the relevant articles, extracted relevant data, and assessed the quality of included studies using the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) risk of bias assessment tool. Results: This systematic review included 11 animal studies, primarily focused on rodent models. Preclinical evidence suggests that Edible Bird’s Nest extract (EBN) may improve performance in several cognitive function tests. Animals treated with EBN appeared to show enhanced spatial memory and learning abilities in experimental settings. At the molecular level, the EBN treatment group showed improved antioxidant capacity and reduced neuroinflammation. Additionally, EBN promoted the expression of neuroprotective factors and enhanced synaptic plasticity. Research suggests that appropriate doses of EBN may have beneficial effects on cognitive enhancement and can alleviate cognitive dysfunction and neuropathological changes. Conclusions: Preliminary evidence from this systematic review suggests that EBN appears to show protective and potentially enhancing effects on cognitive function in animal models. EBN works through multiple mechanisms, including antioxidant and anti-inflammatory effects, as well as promoting the expression of neurotrophic factors and synaptic plasticity. These findings provide initial support for further investigation of EBN as a potential neuroprotective agent and cognitive enhancer. However, there is heterogeneity and methodological limitations in the research, and more standardized studies and preclinical translational research are needed to further validate the application potential of EBN in neuroprotection. These results provide an important reference for developing EBN-based functional foods and supplements for the prevention and adjuvant treatment of cognitive impairment and neurodegenerative diseases.


  • Open Access

    Factors affecting the intention to adopt wearable devices for health monitoring among white-collar workers in Malaysia

    by Seetha Munisamy, Lai Ka Fei, Chang Ke Jun, Lim En Gee, Yip Ning, Hemaniswarri Dewi Dewadas

  • Open Access

    The Role of Societal Influences on Weight Loss Supplement Consumption Among Malaysian Young Adults

    by Willis Chau, Kai Boon Goh, Xuan Ying H’nG, Khay Lok Tong, Ru Jun Wong, Hemaniswarri Dewi Dewadas


  • Open Access

    Effects of house-cultivated edible bird’s nest on immunoglobulin and cytokine release in vitro

    by Mel June Choong, Hemaniswarri Dewi Dewadas, Lay Cheng Lim, Sheela Devi Sukuru, Chee Hong Tan, Soon Keng Cheong, Yang Mooi Lim

    Background and Aim: Edible bird’s nest (EBN) is known as the “Caviar of the East” because of its high nutritional and medicinal values. Nevertheless, its effect on human immunity is yet to be explored. This study examined the effects of EBN’s aqueous extract (EBNE) on human immunity through the modular immune in vitro construct (MIMIC) model consisting of peripheral tissue equivalent (PTE) and lymphoid tissue equivalent (LTE) modules. Materials and Methods: One hundred twenty mL of full blood was obtained from four healthy human volunteers. The human immune system was simulated using an in vitro model, called MIMIC. Under EBNE treatment, monocyte transendothelial migration through reversed endothelial layers was observed. Using PTE and LTE modules, monocytes were differentiated into dendritic cells with lipopolysaccharide, then co-cultured with T- and B-cells for cytokine and immunoglobulin (Ig) production. The human cytokine array G2000 and quantitative human Ig isotyping array were used to identify the cytokine profile and Ig isotypes, respectively. Results: IgE, IgA, and IgG3 levels were significantly raised by EBNE. These cytokines, including brain-derived neurotrophic factor, ciliary neurotrophic factor, glial cell line-derivative neurotrophic factor, insulin-like growth factor 1, and insulin-like growth factor binding protein 4, were generated. Conclusion: For the first time, this work uses a MIMIC model to illustrate the impact of EBNE on human immune response. This new understanding of EBN’s immunoregulatory effect allows for further exploration of how EBN interacts with the human immune system. Keywords: cytokines, edible bird’s nest, immunoglobulins, modular immune in vitro construct model, swiftlets.


  • Open Access

    Acceptability, feasibility and preliminary effectiveness of Picopulse for the treatment of melasma among Malaysian women: A pilot quasi‐experimental

    by Chai Nien Foo, Hemaniswarri Dewi Dewadas, Boon Keat Chin, Tean Chun Teoh, Hong Keat Ong, Yang Mooi Lim

    Background: Women are greatly affected by melasma as compared to men and has a significant negative impact on their quality of life. Thus far, there are no well‐conducted trials for melasma in Malaysia.Objectives: This multicentre quasi‐experimental pilot study aims to determine the acceptability and feasibility of conducting a preliminary effectiveness trial for the Picopulse treatment effect on melasma severity and quality of life in Malaysian women.Methods: Outcome measures were collected from 32 participants aged 18–65 years old presenting dermal melasma with Fitzpatrick skin type III–V from OneDoc Skin Centres in Klang Valley, Malaysia at baseline, 2 weeks, and 4 weeks after intervention. All preliminary effectiveness analyses were performed under the terms of intention‐to‐treat.Results: Overall, the average score of Short Assessment of Patient Satisfaction (SAPS) was 22.2 (SD = 4.8), this demonstrated that the treatment was satisfied and well‐accepted by all patients. The recruitment and retention rates were 48.48% and 71.88%, respectively. Twenty‐five out of 32 patients completed all 10 treatments (78.13%). There were significant mean differences in Melasma severity index (MSI) score reported with partial eta square at 0.79 (p < 0.0001), physician global assessment (PGA) with partial eta square at 0.89 (p < 0.0001), and melasma quality of life scale (MELASQoL) with partial eta square at 0.32 (p < 0.05), from baseline measurement to 4 weeks postintervention. The three most common temporary side effects were pain (M = 0.2, SD = 0.46), redness (M = 0.12, SD = 0.24), and dryness (M = 0.11, SD = 0.17), however, all adverse effects were well‐tolerated and resolved without any treatments.Conclusions: These findings provide promising data that support the acceptability and feasibility for future full‐scale clinical studies. This study was registered with ClinicalTrials.gov (NCT04834167).


  • Open Access

    Molecular Pathways Involved in LRRK2-Linked Parkinson’s Disease: A Systematic Review

    by Ailyn Irvita Ravinther, Hemaniswarri Dewi Dewadas, Shi Ruo Tong, Chai Nien Foo, Yu-En Lin, Cheng-Ting Chien, Yang Mooi Lim

    Parkinson’s disease is one of the most common neurodegenerative diseases affecting the ageing population, with a prevalence that has doubled over the last 30 years. As the mechanism of the disease is not fully elucidated, the current treatments are unable to effectively prevent neurodegeneration. Studies have found that mutations in Leucine-rich-repeat-kinase 2 (LRRK2) are the most common cause of familial Parkinson’s disease (PD). Moreover, aberrant (higher) LRRK2 kinase activity has an influence in idiopathic PD as well. Hence, the aim of this review is to categorize and synthesize current information related to LRRK2-linked PD and present the factors associated with LRRK2 that can be targeted therapeutically. A systematic review was conducted using the databases PubMed, Medline, SCOPUS, SAGE, and Cochrane (January 2016 to July 2021). Search terms included “Parkinson’s disease”, “mechanism”, “LRRK2”, and synonyms in various combinations. The search yielded a total of 988 abstracts for initial review, 80 of which met the inclusion criteria. Here, we emphasize molecular mechanisms revealed in recent in vivo and in vitro studies. By consolidating the recent updates in the field of LRRK2-linked PD, researchers can further evaluate targets for therapeutic application.


  • Challenges in Breast Cancer Control in Malaysia

    by Noor Fatmawati Mokhtar, Hemaniswarri Dewi Dewadas, Juhara Haron, Maya Mazwin Yahya, Bachok Norsa’aDah, Wan Zainira Wan Zain, Sarina Sulong, Jafri Malin Abdullah, Reena Rahayu Md Zin

    : High proportion of late presentation and poor survival of women with breast cancer in Malaysia does not reflect the country’s status as the third richest country in South East Asia. Herein, we examined, and collated research articles related to breast cancer trajectory i.e., primary, secondary, and tertiary prevention in Malaysia to understand, appreciate and recognize the achievements but also gaps which undermine Malaysia’s response in handling the disease. In summary, the integral task for Malaysia is to strategically align research to improve local data (research) on the extent of the country’s breast cancer problem, so that effective, comprehensive, and evidence- based cancer control programs founded on resource level can be generated.